Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion‐dependent pediatric thalassemia patients
- 24 October 2020
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (8) , e13876
Abstract
Background: Early‐onset mixed chimerism (MC) with a high proportion of residual host cells is considered a signal of graft rejection in patients undergoing allogenic hematopoietic stem cell transplantation for transfusion‐dependent thalassemia. In order to prevent graft rejection and minimize the risk of treatment‐related graft‐versus‐host disease (GVHD), we established a hierarchical management system based on chimerism analysis.Method: This retrospective study provides a comprehensive review of the characteristics, interventions, and outcomes of the 38 patients who developed MC after transplantation among the 144 pediatric thalassemia patients between July 2007 and January 2019 at our center.Results: A sibling donor, a blood type‐matched donor, conditioning regimens without fludarabine, and transplants containing 8 total nucleated cells/kg were identified to be associated with the development of MC. Among the 38 patients developing MC, only four patients rejected the grafts. The response rate to donor lymphocyte infusion (DLI, only for patients receiving sibling donor transplantation) and cytokine immunomodulation without DLI was 70.6% and 42.9%, respectively. Patients that developed GVHD after DLI or cytokine therapy had a more significant increase in donor cell chimerism (16%, range 0%‐35%) than those without (8.5%, range −21% to 40%, P = .049). However, even when treatment‐related GVHD was included, patients with MC had a lower cumulative incidence of total acute GVHD than patients with complete donor chimerism (29.2% vs 48.0%, P = .030).Conclusions: Interventions based on chimerism analysis were effective in preventing graft rejection and did not increase treatment‐related GVHD in thalassemia patients with MC.Keywords
Funding Information
- National Natural Science Foundation of China (81100370, 81370603)
This publication has 35 references indexed in Scilit:
- Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemiaBlood Cancer Journal, 2013
- Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell DoseTransplantation and Cellular Therapy, 2013
- Modified donor lymphocyte infusion‐associated acute graft‐versus‐host disease after haploidenticalT‐cell‐replete hematopoietic stem cell transplantation: incidence and risk factorsClinical Transplantation, 2012
- The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantationPediatric Blood & Cancer, 2011
- Recurrence of β-thalassemia major more than 20 years after HLA-identical sibling BMT treated successfully with donor lymphocyte infusionBone Marrow Transplantation, 2011
- Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell diseaseHaematologica, 2010
- Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportionsTransplant Immunology, 2007
- Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor of acute graft-versus-host diseaseTransplantation and Cellular Therapy, 2004
- Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantationBone Marrow Transplantation, 2000
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974